Chronic Electrical Stimulation of Hypothalamus/Fornix in Alzheimer's Disease
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Alzheimer's Disease (AD) is the most common cause of dementia for which no treatment has shown consistent efficacy to stop or slow down the disease. Recent report of enhancement of memory abilities by bilateral chronic deep brain stimulation (DBS) of the fornix in the hypothalamus suggests that neuromodulation of circuits involved in memory processes may have therapeutic implications in AD patients with memory decline.
The primary objectives of this prospective, non-controlled, pilot study are to evaluate the feasibility and safety of DBS in AD patients with mild cognitive and memory impairment, and to evaluate the efficacy of DBS to slow down or stabilize this decline. Five patients with AD (DSM IV) diagnosed less than two years, with mild cognitive decline (MMSE 20-24), and specific impairment of episodic memory will be included in a 2-year period. The evaluation criteria for feasibility will be the proportion of patients undergoing the procedure, chronic stimulation and evaluation process without adverse event (AE). Efficacy will be evaluated using numerous cognitive and memory testing. Changes in behavioral and mood scales, and changes in hypothalamic functions (clinical, biological and hormonal assessment) will evaluate safety and tolerance. Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, and then connected to the generator (Kinetra, Medtronic). Chronic high-frequency stimulation will be delivered immediately after surgery.
The investigators expect to slow down, or to stabilize the spontaneous decline of MMSE and ADAS scores after 6, 12 and 24 months of stimulation. In case of efficacy, DBS might offer to AD patient the possibility to slow down/stabilize their symptoms, which no other treatment can currently offer, and to increase their quality of life.
| Condition | Intervention | Phase |
|---|---|---|
|
Alzheimer's Disease |
Procedure: Bilateral chronic electrical stimulation of the hypothalamus/fornix |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Effect of Deep Brain Stimulation of the Hypothalamus/ Fornix on Memory Impairment in Patients With Alzheimer's Disease |
- Evaluation criteria for feasibility will be the proportion of patients undergoing the procedure, chronic stimulation and evaluation process without adverse event. [ Time Frame: once time ] [ Designated as safety issue: No ]
- Efficacy will be evaluated using numerous cognitive and memory testing. Neuro-imaging changes after stimulation will be evaluate by morphological MRI and functional imaging (PET). Changes in behavioral and mood scales: evaluate safety [ Time Frame: M-3, D-7, D7, M3, M6, M12, M24 ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 5 |
| Study Start Date: | June 2009 |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: ARM A
Bilateral chronic electrical stimulation of the hypothalamus/fornix
|
Procedure: Bilateral chronic electrical stimulation of the hypothalamus/fornix
Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
|
Eligibility| Ages Eligible for Study: | 50 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients with AD (DSM IV) diagnosed less than 2 years
- age between 50 and 65
- mild cognitive decline (MMSE between 20 and 24)
- specific impairment of episodic memory (evaluated by Grober&Buschke scale)
- able to give and sign an informed consent
- affiliated to the French national health and pensions organization
Exclusion Criteria:
- associated DSM I axis pathology
- contra-indication to surgery or MRI
- preoperative MRI abnormalities
- retraction of consent by the patient
- decision of the promoter to stop the study
Contacts and Locations| Contact: Robert Philippe, PhD | +33492037993 | robert.p@chu-nice.fr |
| Contact: Fontaine Denys, PhD | +33492038450 | fontaine.d@chu-nice.fr |
| France | |
| CHU de Nice - 4 avenue Reine Victoria - Hôpital de Cimiez | Recruiting |
| Nice, Alpes-Maritimes, France, 06001 | |
| Contact: ROBERT Philippe, PhD +33492037993 robert.p@chu-nice.fr | |
| Contact: Fontaine Denys, PhD +33492038450 fontaine.d@chu-nice.fr | |
| Principal Investigator: Robert Philippe, PhD | |
| Principal Investigator: Fontaine Denys, PhD | |
| Principal Investigator: | Fontaine Denys, PhD | CHU de Nice - Service de Neurochirurgie - Hôpital Pasteur - 30 av de la voie Romaine - 06 100 Nice |
| Principal Investigator: | ROBERT Philippe, PhD | CHU de Nice - CM2R - Hôpital de cimiez- 4 av reine Victoria 06001 Nice |
More Information
No publications provided
| Responsible Party: | Centre Hospitalier Universitaire de Nice |
| ClinicalTrials.gov Identifier: | NCT00888056 History of Changes |
| Other Study ID Numbers: | 09-PP-01 |
| Study First Received: | April 23, 2009 |
| Last Updated: | June 26, 2012 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Additional relevant MeSH terms:
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 16, 2013